MIAMI & BARRANQUILLA, Colombia / Aug 31, 2023 / Business Wire / Procaps Group (NASDAQ: PROC) (“Procaps”), a leading integrated LatAm healthcare and pharmaceutical services company, announced that it will report its results for the second quarter and six months ended June 30, 2023, before market opens on Tuesday, September 5, 2023.
The Company will host a conference call and webcast at 11:00 a.m. Eastern time, on the same day, to discuss the second quarter and first half 2023 results.
To access the call, please use the following information:
Date: | Tuesday, September 5, 2023 | |||
Time: | 11:00 a.m. ET | |||
Webcast: | ||||
Toll Free dial-in number: | 1-844-204-8586 | |||
Toll/International dial-in number: | 1-412-317-6346 | |||
Conference ID: | Procaps Group |
The conference call will be broadcast live and available for replay at https://bit.ly/45sB21M and via the investor relations section of Procaps’ website here.
A telephone replay will be available approximately two hours after the call and will run through September 12, by dialing 1-877-344-7529 from the U.S., or 1-412-317-0088 from international locations and entering replay pin number: 1873850.
About Procaps Group
Procaps Group, S.A. (“Procaps”) (NASDAQ: PROC) is a leading developer of pharmaceutical and nutraceutical solutions, medicines, and hospital supplies that reach more than 50 countries in all five continents. Procaps has a direct presence in 13 countries in the Americas and more than 5,500 employees working under a sustainable model. Procaps develops, manufactures, and markets over-the-counter (OTC) pharmaceutical products and prescription pharmaceutical drugs (Rx), nutritional supplements and high-potency clinical solutions.
For more information, visit Procaps’ investor relations website investor.procapsgroup.com.
Last Trade: | US$2.66 |
Daily Change: | 0.08 3.10 |
Daily Volume: | 33,789 |
Market Cap: | US$300.100M |
December 26, 2023 November 29, 2023 November 22, 2023 October 23, 2023 October 02, 2023 |
ClearPoint Neuro is a global therapy-enabling platform company providing stereotactic navigation and delivery to the brain. Applications of our ClearPoint Neuro Navigation System include electrode lead placement, placement of catheters, and biopsy. The platform has FDA clearance and is...
CLICK TO LEARN MOREImmix Biopharma is a clinical-stage biopharmaceutical company pioneering a novel class of CAR-T cell therapies and Tissue-Specific Therapeutics targeting oncology and immuno-dysregulated diseases with >75 patients treated to-date. Our lead cell therapy asset is NXC-201...
CLICK TO LEARN MOREEnd of content
No more pages to load
COPYRIGHT ©2023 HEALTH STOCKS HUB